消息面上，2026年开年，中国创新药对外授权交易（BD）市场延续了此前的强劲增长势头，仅第一季 度过半，总交易金额已突破332.8亿美元，首付款规模更超越2025年单季度最高水平。开源证券认为， 创新药板块已回调近两个季度，长期看，较多优质标的估值性价比明显，当前位置建议加大板块配置， 优选已出海的确定性机会及细分赛道景气度高/临床数据优异出海概率大的弹性方向。 此外，东海证券此前指出，2025年创新药板块进入盈利兑现提速期，诺诚健华、荣昌生物等实现扭亏为 盈，三生国健、上海谊众等业绩大幅预增，君实生物等显著减亏，核心驱动主要来自商业化产品快速放 量和BD合作两大主线。创新药板块靓丽的业绩表现，充分验证了国产创新药商业模式的有效性，医保 加持下的核心产品放量成为业绩增长基础，BD等对外合作则成为业绩增厚的重要抓手。 智通财经APP获悉，医药股多数走高。截至发稿，歌礼制药-B(01672)涨6.33%，报17.65港元；康方生物 (09926)涨5.23%，报110.7港元；君实生物(01877)涨4.39%，报21.88港元；百济神州(06160)涨4.37%，报 214.8港元；瑞博生物-B(06938)涨 ...

Core Viewpoint - The announcement of the clinical development of ASC36, a novel oral glucagon-like peptide-1 (GLP-1) receptor agonist, marks a significant advancement for the company in the metabolic disease sector, showcasing its proprietary oral peptide delivery enhancement technology [1] Company Summary - The company's stock, Gilead Sciences-B (01672), saw an increase of nearly 8%, with a current price of HKD 17.72 and a trading volume of HKD 36.79 million [1] - The board of directors has selected ASC36 for clinical development, with plans to submit an Investigational New Drug (IND) application to the FDA in the second quarter of 2026 for obesity treatment [1] - ASC36 is developed using the company's AI-assisted drug discovery technology (AISBDD), representing a key transition from platform capability to candidate drug [1]

Group 1 - The core viewpoint of the news highlights the significant surge in Chinese AI model stocks, particularly with companies like Zhiyu and MiniMax experiencing substantial price increases, with Zhiyu rising over 130% in five trading days and MiniMax increasing over 40% in the same period [1] - The launch of new AI models such as GLM-5 by Zhiyu and Minimax 2.5 by MiniMax is expected to drive further interest and investment in the sector, with additional models from Alibaba and ByteDance anticipated to be released around the Chinese New Year [1] - Korean retail investors are actively purchasing Chinese AI model stocks, indicating a shift in investment preferences towards emerging technology companies, as evidenced by their buying patterns in the Hong Kong stock market [2][4] Group 2 - Data from the Korea Securities Depository shows that Korean investors have favored stocks like MiniMax and various ETFs related to Chinese technology and semiconductors, reflecting a strong interest in these sectors [2][3] - The Korean stock market has seen a remarkable increase, with the composite index rising by 130% since 2025, largely driven by a few major stocks like Samsung Electronics and SK Hynix, which have contributed significantly to the overall market performance [6][7] - The trend of Korean retail investors converting their currency to invest in foreign markets, including the Chinese stock market, has raised concerns about the depreciation of the Korean won, as highlighted by the Bank of Korea [10][11]

Group 1 - Korean investors have shown increasing enthusiasm for Chinese assets, with a total investment exceeding $88 million in the top ten stocks as of February 10, 2026 [3] - The top ten stocks purchased by Korean investors include MINIMAX-WP, Huaxia CSI 300 ETF, and Lanke Technology, with respective investments of $20.67 million, $19.18 million, and $18.64 million [1][2] - There is a noticeable shift in Korean investment focus towards emerging technology companies in China, compared to 2025, where the top investments were in companies like Xiaomi and Alibaba [4] Group 2 - The investment amounts for the top ten stocks in 2026 are as follows: MINIMAX-WP ($20.67 million), Huaxia CSI 300 ETF ($19.18 million), Lanke Technology ($18.64 million), and others, indicating a diverse interest in various sectors [2][4] - In 2025, the top investments were led by Xiaomi Group ($87.75 million) and Global X China Semiconductor ETF ($7.40 million), highlighting a different investment landscape compared to 2026 [5]

Core Insights - Korean investors have shown significant interest in various stocks and ETFs in the Hong Kong Stock Exchange, with the top ten purchases reflecting a diverse investment strategy [1][3] Investment Highlights - The top purchase by Korean investors is MiniMax-WP, with an investment amount of 20.67 million USD [1][3] - The second highest is the 华夏沪深300ETF, attracting 19.18 million USD [1][3] - 澜起科技 follows closely with an investment of 18.65 million USD [1][3] - 安硕恒生科技ETF received 7.36 million USD from Korean investors [1][3] - 南方东英每日杠杆三星电子 saw an investment of 7.33 million USD [1][3] - 英诺赛科 attracted 4.17 million USD in purchases [1][3] - Premia中国科创50ETF received 3.38 million USD [1][3] - 药明合联 was purchased for 3.13 million USD [1][3] - 歌礼制药 saw investments totaling 2.45 million USD [1][3] - Global X中国半导体ETF attracted 2.07 million USD [1][3]

Group 1 - Korean investors are increasingly enthusiastic about allocating assets in China, with over $8.8 million invested in the Hong Kong Stock Exchange as of February 10 [1] - The top ten stocks purchased by Korean investors include MINIMAX-WP, 华夏沪深300ETF, and 澜起科技, among others, indicating a shift towards emerging technology companies [1][2] - The total investment amounts for the top ten stocks are as follows: MINIMAX-WP at $20.67 million, 华夏沪深300ETF at $19.18 million, and 澜起科技 at $18.64 million [2][3] Group 2 - Compared to 2025, Korean investors are now focusing on new emerging industries and technology companies, as evidenced by the change in their top ten investments [3] - In 2025, the top ten net purchases by Korean investors included Xiaomi Group and Global X China Semiconductor ETF, highlighting a different investment focus compared to 2026 [4][5] - The total investment amounts for the top ten stocks in 2025 were significantly higher, with Xiaomi Group at $87.75 million and Global X China Semiconductor ETF at $74.03 million [5]

Group 1 - The Hang Seng Index rose by 0.43%, gaining 116 points to close at 27,299 points, while the Hang Seng Tech Index increased by 1.10% [1] - Xiaomi Group-W (01810) saw a rise of over 4%, with the new generation SU7 expected to launch in April [1] - The first-day listing of Xian Dao Intelligent (00470) increased by 0.44%, while fishing company Lexin Outdoor (02720) surged by 33% on its second day of trading [1] - The Kintor Group (00148) and Kintor Laminates (01888) experienced gains of 5% and 14% respectively, driven by expected high growth in copper-clad laminate performance by 2025 [1] - The precious metals sector saw gains, with Wan Guo Gold Group (03939) rising over 9% to reach a new high, benefiting from increased gold prices [1] - Tungsten prices continued to rise, with tungsten oxide increasing by 20,000 yuan per ton and ammonium paratungstate rising by 10,000 yuan per ton, leading to a surge of over 12% for Jiaxin International Resources (03858) [1] - China Duty Free Group (01880) rose over 5% following a strong start to the Spring Festival travel season for duty-free shopping in Hainan [1] Group 2 - Gilead Sciences-B (01672) increased by over 6%, with plans to submit an IND for ASC36 oral tablets for obesity treatment to the FDA in the second quarter [2] - Jinli Permanent Magnet (06680) rose over 7% as rare earth prices continue to climb, with institutions predicting a dual increase in valuation and performance for the sector [3] - Mongol Mining (00975) surged over 11% as its BKH gold mine ramped up production and dividend restrictions were gradually lifted [4] - Semiconductor Manufacturing International Corporation (00981) fell by 3.63% post-earnings, with Goldman Sachs indicating that its first-quarter gross margin guidance was below expectations [5] - Health 160 (02656) plummeted by 33%, retracting most of its gains for the year, with its total market value briefly falling below 20 billion HKD [6]

Core Viewpoint - The stock of Gilead Sciences-B (01672) has increased over 30% in the month, with a current price of HKD 18.24 and a trading volume of HKD 17.99 million, following the announcement of its first oral glucagon-like peptide-1 receptor agonist, ASC36, entering clinical development [1] Group 1 - The company announced on February 11 that it has selected ASC36 oral tablets for clinical development, with plans to submit an Investigational New Drug (IND) application to the FDA in the second quarter of 2026 for obesity treatment [1] - ASC36 is expected to have superior oral bioavailability and efficacy compared to a recently FDA-approved GLP-1R agonist, potentially allowing for lower dosing [1] - The weight loss effect per milligram of ASC36 peptide is anticipated to be more effective, which may lead to lower manufacturing costs due to scalability advantages [1] Group 2 - ASC36 is developed using the company's proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) technology [1] - The oral tablet formulation of ASC36 has been optimized using the company's proprietary POTENT technology for effective oral peptide delivery [1]

Core Viewpoint - The stock of Gilead Sciences-B (01672) has increased by over 30% in the month, with a current rise of 6.42% to HKD 18.24, driven by the announcement of its first oral glucagon-like peptide-1 receptor agonist, ASC36, entering clinical development [1] Company Developments - On February 11, Gilead Sciences-B announced that its board has selected ASC36 oral tablets for clinical development [1] - The company plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ASC36 in the second quarter of 2026 for the treatment of obesity [1] Product Advantages - ASC36 is expected to have superior oral bioavailability and efficacy compared to a recently FDA-approved GLP-1R agonist, potentially allowing for lower dosing [1] - Each milligram of ASC36 peptide is anticipated to provide better weight loss effects, which may lead to lower manufacturing costs due to scalability advantages [1] Technology and Innovation - ASC36 is developed using Gilead's proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) technology [1] - The oral tablet formulation of ASC36 has been optimized using Gilead's proprietary POTENT technology for effective oral peptide delivery [1]

Major Events - Xian Dao Intelligent (00470) received a subscription rate of 79.54 times for its public offering in Hong Kong, with a final issue price of HKD 45.8 per share [1] - Shishi Pharmaceutical Group (02005) is expected to win bids for 45 products in the national centralized procurement [1] - Gilead Sciences-B (01672) has selected the oral amylin receptor agonist peptide ASC36 for clinical development [1] - China Railway Construction (01186) recently won major projects totaling CNY 451.42 billion [1] - Shoucheng Holdings (00697) invested in Qimiao Labi through its subsidiary fund, focusing on expanding its product matrix around core intellectual property [1] - Minshi Group (00425) plans to establish a joint venture to produce aluminum body frame components [1] - Fubo Group (03738) has reached a strategic cooperation with Xinglu Technology [1] - Jin Xun Resources (03636) plans to increase capital by a total of USD 44 million for its overseas subsidiaries [1] - Changfei Optical Fiber and Cable (06869) experienced abnormal fluctuations in A-share trading, clarifying that it does not engage in CPO-related businesses [1] Operating Performance - SMIC (00981) reported Q4 revenue of USD 2.489 billion, a quarter-on-quarter increase of 4.5%, with a gross margin of 19.2% [1] - PCCW (00008) reported a loss attributable to shareholders of HKD 253 million for the fiscal year 2025, narrowing by 16% year-on-year [1] - WuXi Biologics (02269) issued a positive profit alert, expecting a year-on-year profit increase of approximately 46.3% to CNY 4.908 billion for the fiscal year 2025 [1] - Dongyue Group (00189) issued a positive profit alert, anticipating over 100% year-on-year growth in profit attributable to owners for 2025 [1] - Elephant Future Group (02309) issued a positive profit alert, expecting a mid-term profit attributable to owners of approximately HKD 178 million, reversing from a loss [1] - Sihuan Pharmaceutical (00460) issued a positive profit alert, expecting revenue of no less than CNY 2.5 billion for 2025, with a growth rate exceeding 30% compared to the previous year [1] - Beijing Automotive (01958) expects a net profit attributable to the parent company of approximately CNY 110 million to CNY 130 million for 2025, a year-on-year decrease of about 86.4% to 88.5% [1] - COFCO Joycome (01610) issued a profit warning, expecting a loss attributable to shareholders of approximately CNY 230 million to CNY 350 million, reversing from profit year-on-year [1] - New Town Development (01030) achieved a contract sales amount of approximately CNY 714 million in January, a year-on-year decrease of 29.79% [1] - Yue Yuen Industrial (00551) reported a net operating income of approximately USD 705 million in January, a year-on-year decrease of 12.5% [1] - Baoshan International (03813) reported a cumulative net operating income of CNY 1.748 billion in January, a year-on-year decline of 32.5% [1]